Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.54 |
| ▸ | MMP14 | P50281 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | MMP2 | P08253 | 9/20 | 0.52 |
| ▸ | MMP9 | P14780 | 9/20 | 0.52 |
| ▸ | MMP1 | P03956 | 8/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299383 | 0.88 | MMP13 (0.70) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL8299382 | 0.84 | MMP13 (0.58) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL3934688 | 0.83 | MMP2 (0.52) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL3943162 | 0.83 | MMP13 (0.65) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL13923645 | 0.83 | MMP13 (0.57) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL8303804 | 0.81 | MMP9 (0.49) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL3935381 | 0.81 | MMP9 (0.49) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL14019092 | 0.80 | TP53 (0.42) | MMP13MMP14CYP3A4ADAMTS4KCNH2 | |
| SCHEMBL12463840 | 0.77 | MMP13 (0.53) | MMP13MMP14CYP3A4MMP2MMP9 | |
| SCHEMBL12463630 | 0.76 | MMP13 (0.72) | MMP13MMP14CYP3A4MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | MMP13 8/4885MMP14 15/4885CYP3A4 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.